IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery-Reference-Cited by-同舟云学术

IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery

Published:2016 Issue:9 Volume:6 Page:7575-7581
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Qian Shan¹²³⁴,Zhang Man¹²³⁴,Chen Quanlong¹²³⁴,He Yanying¹²³⁴,Wang Wei¹²³⁴,Wang Zhouyu⁵²³⁴

Affiliation:

1. Department of Pharmaceutical Engineering

2. Xihua University

3. Chengdu 610039

4. P. R. China

5. Department of Chemistry

Abstract

This review highlights the recent advances in research related to the role of IDO in immune escape in cancer and novel small-molecule IDO inhibitors with an emphasis on their chemical structures and modes of action.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2016/RA/C5RA25046C

Reference44 articles.

1. The Targeting of Indoleamine 2,3 Dioxygenase -Mediated Immune Escape in Cancer

2. GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction in Response to Indoleamine 2,3-Dioxygenase

3. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

4. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

5. An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Responsive biomaterials: optimizing control of cancer immunotherapy;Nature Reviews Materials;2023-12-22

2. Recent advances of antitumor leading compound Erianin: Mechanisms of action and structural modification;European Journal of Medicinal Chemistry;2023-12

3. IDO-triggered swellable polymeric micelles for IDO inhibition and targeted cancer immunotherapy;Journal of Controlled Release;2023-11

4. Development and Optimization of a Target Engagement Model of Brain IDO Inhibition for Alzheimer’s Disease;Current Alzheimer Research;2023-10

5. Simultaneous assaying of NLG919, tryptophan and kynurenine by ultra-high performance LC–MS in pharmacokinetics and biodistribution studies;Bioanalysis;2023-03